AngioGenex, Inc. Engages London & Pacific Healthcare to Assist in Attracting Investment Funding

London & Pacific to Leverage Various Capital Resources in the Indian Healthcare Market

London & Pacific Healthcare, Inc. (PINKSHEETS: LDPH), ("London & Pacific"), a corporate finance and development company working with a select group of healthcare companies, is pleased to announce today that it has executed a consulting agreement with New York-based AngioGenex, Inc. (OTCBB: AGGX). The Company will assist AngioGenex in attracting investment capital from India.

AngioGenex is a fully reporting, biotechnology company that engages in the discovery, acquisition and development of anti-cancer agents. The company's drug discovery program is based on technology developed by Dr. Robert Benezra, and licensed from the Memorial Sloan Kettering Cancer Center in New York. With past funding from Kirin Brewery Co. Ltd. and Atypical Bio Ventures, AngioGenex is focused on developing new drug products capable of blocking the Id genes that support the formation of new blood vessels into tumors, a process known as angiogenesis.

"We are extremely excited for this opportunity to work alongside a dynamic bio-technology company such as AngioGenex," commented Stuart Bruck, Executive Chairman and CEO of London & Pacific. He continued, "They are on the cutting edge of revolutionary technology that can change the face of cancer research and to assist with the development of more effective drugs to fight the disease. There are many companies in the Indian market looking to establish alliances with innovative and progressive companies in the West, and London & Pacific can serve as an excellent bridge to these valuable, new relationships."

Richard Salvador, CEO of AngioGenex stated, "AngioGenex is committed to advancing our novel anti-cancer technology to improve patient care for life threatening diseases. The assistance of London & Pacific in leveraging their resources in attracting new funding will help us to advance our development stage products into clinical trials."

About London & Pacific Healthcare, Inc.

London & Pacific Healthcare, Inc., with offices in Los Angeles and London, operates three synergistic operating divisions that capitalize on emerging growth opportunities in the global healthcare industry. Its London-based division City & Westminster Advisers Limited provides comprehensive strategic and financial advisory services to healthcare start-ups, small and mid-sized organizations. Its two California-based divisions, HealthSPAC LLC, acts as an incubator for Special Purpose Acquisition Companies (SPACs), which are "blank check" companies that go public with the intention of merging or acquiring a company with the proceeds of an initial public offering and Healthcare Fund Advisors LLC, provides specialized buy-side sourcing and analysis services to clients that invests in the global healthcare sector. For additional information, please visit the corporate website at

Safe Harbour Disclaimer: This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are "forward-looking statements" are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as: the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels.

London & Pacific Healthcare, Inc.
Michael K. Low

Investor Relations
Kaiden Daniel IR
Dennis Wilson

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.